Microbiological profile of pathogens in spontaneous bacterial peritonitis secondary to liver cirrhosis: a retrospective study

Abstract

Spontaneous bacterial peritonitis (SBP) is an acute bacterial infection of ascitic fluid without an obvious source. The prevalence of SBP in patients with cirrhosis is in the range of 10%–30%. With increasing use of antibiotics, there is a gradual shift in the causative flora of SBP from Gram-negative bacteria to Gram-positive and, more importantly, to drug-resistant bacteria. The aim of this retrospective study on 721 cases was to identify the prevalence of various organisms causing SBP along with their drug sensitivity and resistance patterns. A prevalence of 38.2% culture positivity was observed in our South Indian population. Escherichia coli was the most common pathogen isolated. Third-generation cephalosporins showed high rates of resistance, but a susceptibility of 74.5% to amikacin was found. Nonetheless, 42% of culture-positive isolates exhibited multidrug resistance, the highest rates being seen with Enterococcus faecium (64.2%) and Acinetobacter baumannii (71.4%).

Keywords

Asia bacterial infection digestive disease epidemiology

Background

Antibiotic prophylaxis is advised for patients with chronic liver disease, who have had a previous spontaneous bacterial peritonitis (SBP) and for those with low albumin levels in their ascitic fluid. More Gram-positive and multidrug-resistant bacteria are isolated in cases of SBP, possibly related to the use of prophylactic antibiotics and the rising incidence of nosocomial infections in hospitalised cases secondary to an increase in invasive procedures. As SBP worsens the prognosis in cirrhosis, it is necessary to treat it. However, the poor yield of ascitic fluid culture leads to empiric treatment, usually with third-generation cephalosporins, which is often inadequate.

Methods

Ours was a retrospective case record study over a three-year period from July 2014 to July 2017. After obtaining ethics approval from our institute’s ethical committee at a tertiary care centre in South India, we collected 721 consecutive cases recorded with a clinical diagnosis of spontaneous bacterial peritonitis. The diagnosis of SBP in a known cirrhotic patient was based on the presence of fever, abdominal pain and free fluid in the abdomen and an ascitic fluid polymorphonuclear cell count >250 cells/mm³. Data were collected from the microbiology reports of the ascitic fluid culture (whether negative or positive, and if so the organism isolated) and the bacterial susceptibility to chosen antibiotics. Isolates exhibiting resistance to at least one antibiotic in three or more antibiotic classes were labelled as multidrug-resistant (MDR). Ascitic fluid was cultured by inoculating at least 10 mL in a blood culture bottle. Percentages of Gram-positive and negative bacteria in ascitic fluid and their resistance patterns to seven classes of antibiotics—namely Cephalosporins, Quinolones, Penicillins, Carbapenems, Aminoglycosides, Tetracyclines and Macrolides—were documented. Descriptive statistics were calculated using the SPSS software version 20.0.

Results

Of the 721cases of SBP, 276 (38.2%) had positive ascitic fluid cultures. Gram-negative bacteria (GNB) were isolated from 205 (74.2%); 58 (21%) grew Gram-positive bacteria and 13 (4.7%) had fungal isolates. Common organisms found were Escherichia coli, Acinetobacter baumannii, Enterococcus spp. (including E. faecalis and E. faecium), Klebsiella pneumoniae, Pseudomonas, Enterobacter spp., Staphylococcus aureus, Streptococcus spp. and other GNB. Enterococcus spp. was the most common pathogen (11.9%) among Gram-positive bacteria, followed by Staphylococcus aureus (5.3%) and Streptococcus (3.6%). Candida spp. contributed to most of fungal isolates. Of all the antibiotics tested, the best susceptibility was seen towards Amikacin. Ceftriaxone and Ceftazidime had high resistance rates (Table 1). Of all Acinetobacter baumannii isolates, 71.4% were MDR, as were 30%–60% of K. pneumoniae, Enterobacter spp. and E. coli isolates. Enterococcus faecalis showed >50% sensitivity to Ampicillin, and high levels of Gentamicin and Tetracycline. On the other hand, E. faecium showed a resistance of >50% to these drugs. The antimicrobial activity of Penicillin and Ciprofloxacin against S. aureus was poor, with a resistance of >90%, but erythromycin showed lower rates of resistance. Of the 15 S. aureus isolates, 7 (46.6%) were methicillin-resistant (MRSA). Streptococcus spp. showed 20%–40% resistance to ampicillin. Vancomycin resistance was observed in only a few E. faecium isolates (Table 2). Of Candida spp., 16.6% were resistant to fluconazole, while all were sensitive to amphotericin-B.

Table 1.

Percentage susceptibility of Gram-negative bacteria and proportion of MDR (percentages) in SBP.

Study no.	Antibiotic organism	CTX	CIPRO	CTZ	CFS	MERO	AMI	GENTA	MDR
1	Escherichia coli (n = 78, 28.2%)	16.7	25	22.4	85.8	85.8	93.6	62.2	38.4
2	Acinetobacter baumannii (n = 42, 15.2%)	NT	38.1	23.8	85.8	27.3	47.6	33.3	71.4
3	Klebsiella pneumoniae (n = 31, 11.2%)	29	41.9	29	45	46.2	54.9	45.2	51.6
4	Pseudomonas spp. (n = 28, 10.1%)	NT	68.9	47.2	67.1	54.1	79.4	68.3	32.1
5	Enterobacter species (n = 20, 7.2%)	25	41.9	20	53.4	58.4	75	55	45
6	Citrobacter koseri (n = 4, 1.4%)	25	50	50	0	66.7	75	25	50
7	Flavobacterium species (n = 1, 0.3%)	NT	0	0	NT	0	100	100
8	Non-fermenting Gram-negative bacilli (NFGNB) (n = 1, 0.3%)	NT	0	0	NT	0	0	0

AMI, Amikacin; CTX, Ceftriaxone; CIPRO, Ciprofloxacin; CTZ, Ceftazidime; CFS, Cefoperazone + Sulbactam; GENTA, Gentamicin; MDR, multidrug resistance; MERO, Meropenem; NT, not tested; SBP, spontaneous bacterial peritonitis.

Table 2.

Percentage susceptibility(s) of Gram-positive bacteria and proportion of MDR (percentages) in SBP.

Study no.	Antibiotic organism	AMPI	HLG	TETRA	VANCO	OXA	PEN	CIPRO	ERYTHRO	MDR
1	E. faecalis (n = 19, 6.7%)	68.5	68.8	66.7	100	NT	NT	NT	NT	10.5
2	S. aureus (n = 15, 5.3%)	NT	NT	NT	100	60	6.7	7.7	40	46.6
3	E. faecium (n = 14, 5%)	7.2	21.5	28.6	91	NT	NT	NT	NT	64.2
4	Strep. spp. (n = 9, 3.2%)	80	75	55.6	100	NT	NT	NT	NT	0
5	Beta hemolytic Streptococci (n = 1, 0.3%)	NT	NT	0	NT	NT	100	NT	100	0

AMPI, Ampicillin; Beta-haemolytic, beta-haemolytic streptococcus species; CIPRO, Ciprofloxacin; E. faecalis, Enterococcus faecalis; E. faecium, Enterococcus faecium; ERYTHRO, Erythromycin; HLG, high-level gentamicin; MDR, multidrug resistance; NT, not tested; OXA, Oxacillin; PEN, Penicillin; S. aureus, Staphylococcus aureus; SBP, spontaneous bacterial peritonitis; Strep. spp., Streptococcus species; TETRA, Tetracycline; VANCO, Vancomycin.

Discussion

Spontaneous bacterial peritonitis is treated with antibiotics, once the ascitic fluid white cell count exceeds 250 cells/mm³.¹ The outcome depends on the causative organism and its antibiotic susceptibility. Our frequency of Gram-negative organisms was similar to other studies done worldwide.^2,3 Recent reports from Asia and European nations also suggest that an increasing proportion of SBP is caused by gram-positive pathogens.^4–7

Poor antimicrobial coverage with cephalosporins has also been reported earlier, but in the range of 10%–45%.^8–11 As ours is a tertiary care referral centre, it is possible that patients may have been partially treated elsewhere previously. Nonetheless, vancomycin resistant Enterococci were fewer than in a German study,¹² and we did not see Vancomycin resistance in Staphylococci as in a Chinese study.¹³

The distribution of multidrug resistance differs in various countries and healthcare facilities, and depends on the antibiotics used and epidemiology of the causative pathogens in specific areas.

Thus, empirical treatment strategies need regular local re-evaluation.^14,15

One of the major limitations of this study was the lack of data on the proportion of patients who were on quinolone prophylaxis for SBP. Management strategies and outcome of such should be the focus of future research.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Mukta Wyawahare

References

European Association for the Study of Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397–417.

Piano

Singh

Caraceni

, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide. Gastroenterology 2019; 156: 1368–1380.

Klímová

Padilla

Ávila

, et al. Epidemiology of bacterial infections in patients with liver cirrhosis. Experience in a Spanish tertiary health center. Biomedica 2016; 36: 121–132.

Guo

Shi

Wang

, et al. Emerging Gram-positive bacteria and drug resistance in cirrhosis patients with spontaneous bacterial peritonitis: A retrospective study. Exp Ther Med 2019; 17: 4568–4576.

Addo Smith

Yau

Russo

, et al. Bacteremia in patients with liver cirrhosis: prevalence and predictors of multidrug resistant organisms. J Clin Gastroenterol 2018; 52: 648–654.

Friedrich

Nüssle

Rehlen

, et al. Microbiology and resistance in first episodes of spontaneous bacterial peritonitis: implications for management and prognosis. J Gastroenterol Hepatol 2016; 31: 1191–1195.

Alexopoulou

Vasilieva

Agiasotelli

, et al. Extensively drug-resistant bacteria are an independent predictive factor of mortality in 130 patients with spontaneous bacterial peritonitis or spontaneous bacteremia. World J Gastroenterol 2016; 22: 4049–4049.

Sunjaya

Lennon

Shah

, et al. Prevalence and predictors of third-generation cephalosporin resistance in the empirical treatment of spontaneous bacterial peritonitis. Mayo Clin Proc 2019; 94: 1499–1508.

Oliveira

Carrera

Petry

, et al.

High prevalence of multidrug resistant bacteria in cirrhotic patients with spontaneous bacterial peritonitis: is it time to change the standard antimicrobial approach?

Can J Gastroenterol Hepatol 2019; 2019: e 6963910–e 6963910.

10.

Sarwar

Tarique

Waris

, et al. Cephalosporin resistance in community acquired spontaneous bacterial peritonitis. Pak J Med Sci 2019; 35: 4–9.

11.

Ardolino

Wang

Patwardhan

. Evidence of significant ceftriaxone and quinolone resistance in cirrhotics with spontaneous bacterial peritonitis. Dig Dis Sci 2019; 64: 2359–2367.

12.

Ferstl

Müller

Filmann

, et al. Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms. Infect Drug Resist 2018; 11: 2047–2061.

13.

Ning

Zhang

, et al. Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis. BMC Infect Dis 2018; 18: 253–253.

14.

Fiore

Gentile

Maraolo

, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30: 329–336.

15.

Rostkowska

Szymanek-Pasternak

Simon

. Spontaneous bacterial peritonitis - therapeutic challenges in the era of increasing drug resistance of bacteria. Clin Exp Hepatol 2018; 4: 224–231.